Press Releases
Search
-
03 Sep 2013
bioMérieux makes a significant acquisition in molecular biology in the U.S.
With the acquisition of BioFire, bioMérieux consolidates its position as a major player in infectious disease diagnostics With a complete range of technologies for clinical microbiology diagnostics, b...
-
22 Aug 2013
bioMérieux Announces U.S. FDA Clearance for VITEK® MS, a Revolutionary Technology which Reduces Microbial Identification from Days to Minutes Reinforcing Medical Value of Diagnostics
Marcy L’Etoile (France) and Durham, NC - August 21, 2013 - bioMérieux today announced that it has been granted U.S. FDA 510(k) de novo clearance for VITEK® MS, the first clinical mass spectrometry MAL...
-
18 Jul 2013
First-Half 2013 Business Review
Sharp acceleration in organic growth in the second quarter, up 4% Double-digit growth in emerging markets up 14% Sustained gains in North America Industrial application sales up 11% 2013 organic sales...
-
27 Jun 2013
International Experts Join Forces against Superbugs at the 4th World Forum on Healthcare-Associated Infections and Antimicrobial Resistance
bioMérieux commits to supporting expert-defined global priorities...
-
20 Jun 2013
bioMérieux receives CE marking for VIDAS® 3, the new generation of VIDAS®
Marcy l'Étoile, France, June 20, 2013 — bioMérieux, a world leader in the field of in vitro diagnostics, announces that VIDAS® 3, the new generation of VIDAS®, has been granted CE marking. This instru...
-
30 May 2013
bioMérieux Receives FDA Approval for THxIDTM-BRAF Companion Diagnostic Test
The only CE-marked and FDA-approved BRAF test able to simultaneously detect 2 BRAF mutations, V600E and V600K providing high medical value information to select treatment for metastatic melanoma patie...